Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial

Lancet Infectious Diseases
Jun 2020 Volume 20 Number 6 p629-754, e116-e147
http://www.thelancet.com/journals/laninf/issue/current

 

Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial
Milagritos D Tapia, et al on behalf of the Zaire EBola Research Alliance group